Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Ian Chau

Ian Chau

The Royal Marsden NHS Foundation Trust, London

5-year follow-up of CheckMate 648: NIVO plus chemo or IPI vs chemo as 1L treatment for advanced ESCC

5-year follow-up of CheckMate 648: NIVO plus chemo or IPI vs chemo as 1L treatment for advanced ESCC

Ian Chau • 20 Oct 2025

SKYSCRAPER-07: atezolizumab with or without tiragolumab in patients with unresectable ESCC

SKYSCRAPER-07: atezolizumab with or without tiragolumab in patients with unresectable ESCC

Ian Chau • 20 Oct 2025

ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments

ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments

Ian Chau • 2 Jun 2024

45-month CheckMate 648 results show nivolumab combos' sustained benefits in ESCC

45-month CheckMate 648 results show nivolumab combos' sustained benefits in ESCC

Ian Chau • 2 Jun 2024

Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648

Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648

Ian Chau • 2 Jun 2024

CAR-T cell therapy for the treatment of gastric cancer

CAR-T cell therapy for the treatment of gastric cancer

Ian Chau • 9 Jun 2022

Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer

Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer

Ian Chau • 9 Jun 2022

Expanded efficacy and safety analyses from CheckMate 648

Expanded efficacy and safety analyses from CheckMate 648

Ian Chau • 9 Jun 2022

CheckMate 648: 1L IO-IO in advanced esophageal squamous cell carcinoma

CheckMate 648: 1L IO-IO in advanced esophageal squamous cell carcinoma

Ian Chau • 28 Jun 2021